Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three ...

Despite being thrown off its rhythm twice already, Johnson & Johnson is making another go of its “Texas two-step” strategy to ...

More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

Telix Pharmaceuticals tallied its third acquisition of the year with a deal worth up to $250 million for Florida-based RLS ...

For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the ...

Swiss anti-aging biotech Rejuveron is seeking its rejuvenation as it morphs into Centenara Labs. | Swiss anti-aging biotech ...

Unlock the potential of patient support data with effective information governance. Manage risks, ensure compliance, and ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...